Literature DB >> 19115383

Live imaging of amyotrophic lateral sclerosis pathogenesis: disease onset is characterized by marked induction of GFAP in Schwann cells.

A Florence Keller1, Mathieu Gravel, Jasna Kriz.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a late-onset neurological disease characterized by progressive loss of motor neurons. At present, the pathological events precipitating disease onset and the exact pattern of disease progression are not fully understood. Recent studies suggest that glial cells, in particular activated astrocytes, can release factors that can directly kill motor neurons. To further investigate the involvement of glial cells (astrocytes and Schwann cells) in the pathogenesis of ALS, we generated ALS-(GFAP-luciferase/SOD(G93A)) reporter mouse in which upregulation of glial fibrillary acidic protein (GFAP) can be visualized from live animals throughout the different stages of disease. Our results suggest that the disease in mice is initiated simultaneously in the spinal cord and in the peripheral nerves and is characterized by several cycles of GFAP upregulation. Immunohistochemical analysis confirmed that the induction GFAP bioluminescence signals were associated with the significant increases in GFAP immunoreactivity. The first pathological GFAP signals occurring at 25-30 days were asymptomatic and detectable at the level of lumbar spinal cord projections and at the periphery. These early events were then followed by GFAP promoter inductions that were associated with the distinct clinical symptoms. As expected, the onset of paralysis (112 days) was associated with the gradual and marked GFAP upregulation in the spinal cord. Interestingly, however, the disease onset (90 days) was characterized by sharp and synchronized induction of GFAP in peripheral nerve Schwann cells suggesting that peripheral nerves pathology/denervation and associated Schwann cell stress may play an important role in the ALS pathogenesis. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19115383     DOI: 10.1002/glia.20836

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  48 in total

1.  Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials.

Authors:  Albert C Ludolph; Sarah Jesse
Journal:  Ther Adv Neurol Disord       Date:  2009-09       Impact factor: 6.570

2.  Biaryl amides and hydrazones as therapeutics for prion disease in transgenic mice.

Authors:  Duo Lu; Kurt Giles; Zhe Li; Satish Rao; Elena Dolghih; Joel R Gever; Michal Geva; Manuel L Elepano; Abby Oehler; Clifford Bryant; Adam R Renslo; Matthew P Jacobson; Stephen J Dearmond; B Michael Silber; Stanley B Prusiner
Journal:  J Pharmacol Exp Ther       Date:  2013-08-21       Impact factor: 4.030

Review 3.  Glial cells in amyotrophic lateral sclerosis.

Authors:  T Philips; J D Rothstein
Journal:  Exp Neurol       Date:  2014-05-22       Impact factor: 5.330

Review 4.  New perspectives on amyotrophic lateral sclerosis: the role of glial cells at the neuromuscular junction.

Authors:  Danielle Arbour; Christine Vande Velde; Richard Robitaille
Journal:  J Physiol       Date:  2016-12-01       Impact factor: 5.182

5.  Bioluminescence Imaging of Neuroinflammation in Transgenic Mice After Peripheral Inoculation of Alpha-Synuclein Fibrils.

Authors:  Sara Breid; Maria E Bernis; Julius B Tachu; Maria C Garza; Holger Wille; Gültekin Tamgüney
Journal:  J Vis Exp       Date:  2017-04-13       Impact factor: 1.355

6.  Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL-34, and SCF in amyotrophic lateral sclerosis.

Authors:  Emiliano Trias; Mariángeles Kovacs; Peter H King; Ying Si; Yuri Kwon; Valentina Varela; Sofía Ibarburu; Ivan C Moura; Olivier Hermine; Joseph S Beckman; Luis Barbeito
Journal:  Glia       Date:  2019-12-20       Impact factor: 7.452

7.  Bioluminescence imaging in live cells and animals.

Authors:  Jack K Tung; Ken Berglund; Claire-Anne Gutekunst; Ute Hochgeschwender; Robert E Gross
Journal:  Neurophotonics       Date:  2016-04-05       Impact factor: 3.593

8.  Acute glial activation by stab injuries does not lead to overt damage or motor neuron degeneration in the G93A mutant SOD1 rat model of amyotrophic lateral sclerosis.

Authors:  Masatoshi Suzuki; Sandra Klein; Elizabeth A Wetzel; Michael Meyer; Jacalyn McHugh; Craig Tork; Antonio Hayes; Clive N Svendsen
Journal:  Exp Neurol       Date:  2009-12-11       Impact factor: 5.330

9.  Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis.

Authors:  Yi Zhang; Anna Cook; Jinho Kim; Sergei V Baranov; Jiying Jiang; Karen Smith; Kerry Cormier; Erik Bennett; Robert P Browser; Arthur L Day; Diane L Carlisle; Robert J Ferrante; Xin Wang; Robert M Friedlander
Journal:  Neurobiol Dis       Date:  2013-03-26       Impact factor: 5.996

10.  Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis.

Authors:  David J Graber; William F Hickey; Brent T Harris
Journal:  J Neuroinflammation       Date:  2010-01-28       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.